Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Stelara Ustekinumab Psoriasis List with clinical criteria and/or conditions Complete
Silkis Calcitriol Psoriasis, mild to moderate plaque Do not list Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque List with clinical criteria and/or conditions Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque N/A Complete
Siliq brodalumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Duobrii Halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Ilumya tildrakizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Skyrizi risankizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete